Therapeutic Advances in Medical Oncology最新文献

{"title":"Corrigendum to \"Selpercatinib in Chinese patients with <i>RET</i>-fusion-positive non-small-cell lung cancer: updated efficacy and safety analysis from the LIBRETTO-321 phase II trial\".","authors":"","doi":"10.1177/17588359251327771","DOIUrl":"https://doi.org/10.1177/17588359251327771","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/17588359241307199.].</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251327771"},"PeriodicalIF":4.3,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current and future perspectives in extensive-stage small-cell lung cancer.","authors":"Jeong Uk Lim, Woo Kyung Ryu, Nuri Park, Juwhan Choi, Eunyoung Lee, Sang-Yun Lee, Jun Hyeok Lim","doi":"10.1177/17588359251326705","DOIUrl":"https://doi.org/10.1177/17588359251326705","url":null,"abstract":"<p><p>Small-cell lung cancer (SCLC) is a highly aggressive and rapidly proliferative malignancy that has historically had limited therapeutic advancements. Recent advancements in the understanding of SCLC have led to attempts at subtyping the disease based on transcription factor characteristics, offering new insights into its biology and potential therapeutic targets. In addition, significant progress has been made in developing treatment regimens, providing new hope for improved patient outcomes. The introduction of immune checkpoint inhibitors, such as atezolizumab and durvalumab, in combination with traditional chemotherapy, has marked a significant advancement, demonstrating improved overall survival and progression-free survival compared to chemotherapy alone. Despite these advancements, the prognosis for extensive-stage SCLC (ES-SCLC), the more advanced form of SCLC, remains poor, highlighting the critical need for ongoing research and the development of novel therapeutic strategies. New treatment modalities, such as lurbinectedin and anti-Delta-like Canonical Notch Ligand 3 antibodies, are now included in the treatment options for refractory SCLC, and many more treatment strategies involving combination therapies are being studied. Advances in molecular profiling and the identification of biomarkers are aiding in the development of personalized treatment approaches. This review focuses on these recent advancements and emerging strategies in the treatment of ES-SCLC.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251326705"},"PeriodicalIF":4.3,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143650227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of candidates with hepatocellular carcinoma to receive TACE combined with MWA by assessing tumor burden and radiologic features.","authors":"Chao An, Lujun Shen, Qifeng Chen, Yiquan Jiang, Chen Li, He Ren, Peihong Wu, Xi Liu","doi":"10.1177/17588359251324052","DOIUrl":"https://doi.org/10.1177/17588359251324052","url":null,"abstract":"<p><strong>Background: </strong>There is still no noninvasive, automated, and accurate model for guiding physicians in the decision-making of transarterial chemoembolization combined with microwave ablation (TACE-MWA) in intermediate-stage hepatocellular carcinoma (HCC).</p><p><strong>Objectives: </strong>To develop a prognostic score based on the tumor burden and radiomic features for the prediction of the long-term survival of patients with intermediate-stage HCC after TACE-MWA.</p><p><strong>Methods: </strong>From June 2008 to October 2022, a total of 2189 consecutive patients from seven tertiary-care hospitals with intermediate-stage HCC who received initial TACE combined with MWA were enrolled. Among them, 2189 were divided into training cohort (<i>N</i> = 1753), and internal test cohort (<i>N</i> = 436) in a single center, and 316 patients were assigned to external test cohort in another 6 centers. A prognostic scoring system was constructed using tumor burden and radiologic features (TBR) and compared with conventional predicting systems.</p><p><strong>Results: </strong>In training cohort, multivariate Cox regression analysis suggested that tumor burden (hazard ratio (HR), 0.693; 95% confidence interval (CI): 0.505, 0.814; 1 point per 1.0 increase, <i>p</i> = 0.024), radiologic features (HR, 0.349; 95% CI: 0.236, 0.517; <i>p</i> < 0.001), and alpha-fetoprotein (HR, 1.629; 95% CI: 1.280, 2.073; <i>p</i> < 0.001) were independent prognostic factors for OS. A prognostic model that comprises TBR was built, which showed significantly higher AUC values than other clinical stagings in all three cohorts. Moreover, the TBR score provided greater net benefit across the range of reasonable threshold probabilities than other models. Based on cutoff values of 32 and 74 centiles of the TBR score, the cohort was divided into low-, middle-, and high-risk strata, which provide consistent performance in survival discrimination across different patient subgroups.</p><p><strong>Conclusion: </strong>The TBR score serves as an efficient instrument for risk stratification, guiding the course of adjuvant targeted and immunotherapies for HCC patients undergoing TACE-MWA combined treatment.</p><p><strong>Design: </strong>A retrospective, multi-institutional study.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251324052"},"PeriodicalIF":4.3,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909676/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143650603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA study.","authors":"Fumihiko Kinoshita, Shigeru Tanzawa, Toshihiro Misumi, Hiroshige Yoshioka, Eisaku Miyauchi, Kiichiro Ninomiya, Yasunori Murata, Masafumi Takeshita, Masafumi Yamaguchi, Shunichi Sugawara, Yosuke Kawashima, Kazuki Hashimoto, Masahide Mori, Akihiko Miyanaga, Anna Hayashi, Hisashi Tanaka, Ryoichi Honda, Masafumi Nojiri, Yuki Sato, Ken Yamamoto, Ken Masuda, Toshiyuki Kozuki, Takahisa Kawamura, Takuji Suzuki, Teppei Yamaguchi, Kazuhiro Asada, Satoshi Tetsumoto, Hiroshi Tanaka, Satoshi Watanabe, Yukihiro Umeda, Kakuhiro Yamaguchi, Shoichi Kuyama, Kosuke Tsuruno, Yuki Misumi, Hiroshi Kuraishi, Ken Yoshihara, Akira Nakao, Akihito Kubo, Toshihiko Yokoyama, Kana Watanabe, Nobuhiko Seki","doi":"10.1177/17588359241312503","DOIUrl":"https://doi.org/10.1177/17588359241312503","url":null,"abstract":"<p><strong>Background: </strong>Skin disorders are major adverse events associated with necitumumab plus gemcitabine and cisplatin (Neci + GC) administration. However, the prognostic effect of skin disorders in patients with lung squamous cell carcinoma (LSCC) administered Neci + GC is unclear.</p><p><strong>Objectives: </strong>We examined this prognostic effect in patients with LSCC, and the usefulness of minocycline administration.</p><p><strong>Design: </strong>This was a sub-analysis of the retrospective multicenter NINJA study.</p><p><strong>Methods: </strong>We performed a landmark survival analysis according to the presence of skin disorders at Day 30 of treatment and examined the usefulness of minocycline for treating skin disorders.</p><p><strong>Results: </strong>Among the 93 patients, 62 (66.7%) had a skin disorder at Day 30. Nineteen, 30, and 13 patients experienced Grade 1, 2, and 3 skin disorders, respectively. The overall survival (OS) and progression-free survival (PFS) of patients with skin disorders at Day 30 were longer than those of patients without skin disorders (median OS: 434 vs 278 days, <i>p</i> = 0.0201; median PFS: 148 vs 82 days, <i>p</i> = 0.0835). Multivariable analysis showed that a skin disorder at Day 30 was an independent prognostic factor for both OS (<i>p</i> = 0.0044) and PFS (<i>p</i> = 0.0514). Of the 62 patients with skin disorders at Day 30, 38 (61.3%) were taking minocycline, and their time to treatment failure (TTF) was better than that in patients not taking minocycline (median TTF: 148 vs 101 days, <i>p</i> = 0.0495).</p><p><strong>Conclusion: </strong>A skin disorder within 30 days was a favorable prognostic factor for patients with LSCC administered Neci + GC. Additionally, minocycline administration may be beneficial in patients who develop skin disorders within 30 days.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359241312503"},"PeriodicalIF":4.3,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909677/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143650673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The dual role of gut microbiota in pancreatic cancer: new insights into onset and treatment.","authors":"Huijuan Cheng, Hongkai Guo, Chengming Wen, Guodong Sun, Futian Tang, Yumin Li","doi":"10.1177/17588359251324882","DOIUrl":"https://doi.org/10.1177/17588359251324882","url":null,"abstract":"<p><p>Pancreatic cancer ranks among the most lethal digestive malignancies, exhibiting a steadily increasing incidence and mortality worldwide. Despite significant advances in cancer research, the 5-year survival rate remains below 10%, predominantly due to delayed diagnosis and limited therapeutic options. Concurrently, the gut microbiota-an integral component of host physiology-has emerged as a crucial player in the pathogenesis of pancreatic cancer. Mounting evidence indicates that alterations in gut microbial composition and function may influence tumor initiation, progression, and response to therapy. This review provides an in-depth examination of the intricate interplay between the gut microbiome and pancreatic cancer, highlighting potential diagnostic biomarkers and exploring microbiome-targeted therapeutic strategies to improve patient outcomes.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251324882"},"PeriodicalIF":4.3,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909682/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143650697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunotherapy in advanced, <i>KRAS</i> G12C-mutant non-small-cell lung cancer: current strategies and future directions.","authors":"Nadia Ghazali, Marina C Garassino, Natasha B Leighl, Christine M Bestvina","doi":"10.1177/17588359251323985","DOIUrl":"https://doi.org/10.1177/17588359251323985","url":null,"abstract":"<p><p>Kirsten rat sarcoma (<i>KRAS</i>) mutations are present in up to 25% of non-small-cell lung cancer (NSCLC). <i>KRAS</i> G12C is the most common type of mutation, representing approximately half of the cases in <i>KRAS</i>-mutant NSCLC. Mutations in <i>KRAS</i> activate the RAF-MEK-ERK pathway, leading to increased cell proliferation and survival. Recent advances in drug development have led to the approval of KRAS G12C inhibitors sotorasib and adagrasib. This review explores the emerging therapeutic strategies in <i>KRAS</i> G12C-mutant NSCLC, including dual checkpoint blockade and combinations with checkpoint inhibitors, with a focus on the setting of advanced disease.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251323985"},"PeriodicalIF":4.3,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11907553/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143650616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing precision in sarcoma diagnosis: nCounter fusion panel implementation in a middle-income country.","authors":"Flávia Escremim de Paula, Murilo Bonatelli, Monise Tadin Dos Reis, Karla Emília de Sá Rodrigues, Léon C van Kempen, Gustavo Ramos Teixeira, Rui Manuel Reis","doi":"10.1177/17588359251318159","DOIUrl":"https://doi.org/10.1177/17588359251318159","url":null,"abstract":"<p><strong>Background: </strong>Sarcoma diagnosis is challenging due to numerous subtypes with similar histopathological features and the high cost of fusion detection methods, particularly in middle-income countries.</p><p><strong>Objectives: </strong>To implement a cost-effective custom-based nCounter approach previously validated for fusion analysis of suspected sarcoma in Brazil.</p><p><strong>Design and methods: </strong>RNA isolated from 56 routine sarcomas, which were formalin-fixed and paraffin-embedded, was analyzed using a custom nCounter assay that detects 174 common sarcoma gene fusions. The results were compared to fluorescence in situ hybridization (FISH)/next-generation sequencing (NGS) and clinicopathological data.</p><p><strong>Results: </strong>The nCounter assay was conclusive in 98.2% of cases, identifying 25 gene fusions with 82.5% accuracy, 76.6% sensitivity, and 100% specificity compared to FISH/NGS.</p><p><strong>Conclusion: </strong>Although it does not identify all sarcoma fusions, especially for rare subtypes, the present nCounter assay is a rapid, affordable, and accurate tool for sarcoma diagnosis in resource-limited settings.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251318159"},"PeriodicalIF":4.3,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11907538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143650420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multivariable model for predicting 5-year survival in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective study.","authors":"Qi-An Wang, I-Lin Tsai, Chien-Yu Lin, Po-Lan Su, Chien-Chung Lin, John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Cheng-Ta Yang, Chiao-En Wu","doi":"10.1177/17588359251321901","DOIUrl":"https://doi.org/10.1177/17588359251321901","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. In Asian populations, epidermal growth factor receptor (EGFR) mutations are particularly prevalent, leading to the development of EGFR tyrosine kinase inhibitors (TKIs) to improve patient outcomes. While extensive research has been conducted on the prognosis of patients receiving EGFR-TKIs, the estimation of 5-year survival in this population remains an underexplored area.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objectives: &lt;/strong&gt;This study aimed to provide real-world evidence and conduct a comprehensive analysis of the determinants influencing the 5-year survival rate in patients with EGFR-mutated NSCLC. Considering the factors identified in this study, a scoring system was developed to predict the likelihood of patients achieving this goal.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design: &lt;/strong&gt;A retrospective cohort study utilizing a training cohort of 1,873 patients and a validation cohort of 484 patients.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A logistic regression model was constructed to evaluate the weighting of factors and develop a scoring system. The Kaplan-Meier model estimated the overall survival probability, and patients were categorized into four risk groups based on their likelihood of five-year survival. The prediction performance of both the training and validation cohorts was evaluated using the area under the curve (AUC), accuracy, precision, sensitivity, specificity, and F1-score.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Results indicated that age &gt; 65 years; performance score of 2-4; metastasis to the liver, brain, bone, or pleura; and poor disease control were associated with a decreased likelihood of 5-year survival. The estimated 5-year survival rate was 23.4% (odds ratio [OR]: 20.56; 95% confidence interval [CI]: 9.06-46.64; p &lt; 0.0001), 16.1% (OR: 12.88; 95% CI: 5.82-28.49; p &lt; 0.0001), 7.2% (OR: 5.23; 95% CI: 2.36-11.60; p &lt; 0.0001), and 1.5% (OR: reference) for the low-risk, intermediate-risk, high-risk, and very-high-risk groups, respectively. The validation cohort further confirmed these findings, showing survival probabilities of 52.6% (OR: 96.67; 95% CI: 11.07-844.23; p &lt; 0.0001), 21.3% (OR: 23.49; 95% CI: 3.13-176.46; p = 0.002), 14.9% (OR: 15.21; 95% CI: 2.03-114.25; p = 0.008), and 1.1% (OR: reference) for the low-risk, intermediate-risk, high-risk, and very-high-risk groups, respectively. The training cohort demonstrated an AUC of 0.79 (95% CI: 0.75-0.82) and a model quality score of 0.75, indicating good predictive performance. Calibration plots demonstrated a good fit for the scoring system. For the external validation cohort, the AUC, precision, sensitivity, and specificity were 0.71, 0.74, 0.35, 0.33, respectively. The model achieved an F1-score of 0.47, reflecting adequate performance in predicting 5-year survival probabilities.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;This study identified critical prognostic factors and developed a validated sco","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251321901"},"PeriodicalIF":4.3,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11907550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143650626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of sacituzumab govitecan versus treatment of physician's choice in previously treated HR+ and HER2- mBC: a meta-analysis of TROPiCS-02 and EVER-132-002 trials.","authors":"Oleg Gluz, Binghe Xu, Rita Nanda, Anandaroop Dasgupta, Ankita Kaushik, Wendy Verret, Akanksha Sharma, Barinder Singh, Hope S Rugo","doi":"10.1177/17588359251320285","DOIUrl":"https://doi.org/10.1177/17588359251320285","url":null,"abstract":"<p><strong>Background and objective: </strong>TROPiCS-02 and EVER-132-002 are phase III randomized controlled trials (RCTs) comparing sacituzumab govitecan (SG) to treatment of physician's choice (TPC) in patients with hormone receptor-positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) locally recurrent inoperable or metastatic breast cancer (mBC) who have progressed after two to four prior chemotherapy regimens. TROPiCS-02 enrolled mainly non-Asian patients, whereas EVER-132-002 consisted of only Asian participants. In this study, we compared the efficacy outcomes for SG to TPC via a meta-analysis of the two trials.</p><p><strong>Methods: </strong>Preferred Reporting Items for Systematic Reviews and Meta-Analyses of Individual Participant Data (PRISMA-IPD) guidelines were followed. IPD from the trials were assessed for integrity, consistency, imbalances, or missing values and were combined to estimate pooled and relative treatment effects for comparison of overall survival (OS), progression-free survival (PFS), duration of response (DOR), objective response rate (ORR), and clinical benefit rate (CBR) in the overall, cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) pre-treated, and fast-progressors population (defined as the subgroup of patients with duration of prior CDK4/6i ⩽12 months).</p><p><strong>Results: </strong>In general, TROPiCS-02 and EVER-132-002 had a similar distribution of baseline population characteristics except for prior CDK4/6i treatment and geography. In the overall meta-analytic model, SG showed a significant improvement over TPC in PFS (hazard ratio (HR), 0.62 (95% confidence interval (CI): 0.50-0.77); <i>p</i> < 0.001) and OS (HR, 0.66 (95% CI: 0.55-0.80); <i>p</i> < 0.001). Similar patterns in efficacy were observed in both fast-progressors as well as patients previously treated with CDK4/6i. In the overall population, SG was associated with statistically significantly higher ORR (rate ratio (RR), 1.45 (95% CI: 1.09-1.95); <i>p</i> = 0.012), CBR (RR, 1.59 (95% CI: 1.28-1.97); <i>p</i> < 0.001), and DOR (HR, 0.55 (95% CI: 0.32-0.95); <i>p</i> = 0.032) compared to TPC.</p><p><strong>Conclusion: </strong>In conclusion, this meta-analysis confirms that SG significantly improves clinical outcomes in patients with HR+/HER2- mBC, including those pre-treated with CDK4/6i and fast-progressors when compared to TPC. These findings extend previous research, supporting the integration of SG into clinical practice guidelines at a global level for treating the HR+/HER2- mBC population irrespective of status and duration of prior CDK4/6i exposure.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251320285"},"PeriodicalIF":4.3,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11907608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143650179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone metastasis in follicular dendritic cell sarcoma-a rare site in a rare disease: case report and review of literature.","authors":"Tsielestina Poulli, Christos Cortas, Antonios Neokleous, Irene Tsappa, Pampina Pilavaki, Morfo Georgiou, Chloe Symeonidou, Nicos Katodritis, Anastasia Constantinidou","doi":"10.1177/17588359251318863","DOIUrl":"10.1177/17588359251318863","url":null,"abstract":"<p><p>Follicular dendritic cell sarcoma (FDCS) is a rare sarcoma subtype, presenting as a relatively indolent disease in most cases. Given its rarity, clinicopathological characteristics and behavior as well as treatment, are reported in the literature through case reports and case series. Bone metastasis in FDCS is extremely rare and the outcome of the disease in this group of patients is unknown. We report one case of FDCS with bone involvement as the first site of metastasis. We present the progression of the disease over a period of almost a decade in a detailed manner, particularly the therapies used including immunotherapy with checkpoint inhibitors. In parallel, we provide a comparison with other cases of FDCS metastatic to the bone (total of eight cases) through a systematic review of the literature on the clinical and pathological manifestations as well as the outcomes of all such cases reported to date, to the best of our knowledge. These cases highlight the challenges associated with setting the correct diagnosis at presentation, the lack of evidence to support the role of adjuvant therapy following primary surgery but also the role and/or sequence of systemic options in the advanced setting.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251318863"},"PeriodicalIF":4.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143557472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}